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ABSTRACT 
 
Lisa Smeester: Chronic Early Childhood Exposure to Inorganic Arsenic is Associated with a 
TNF-mediated Proteomic Signaling Response 
(Under the direction of Rebecca C. Fry) 
 
Exposure to inorganic arsenic (iAs) in drinking water remains a global issue of concern 
and is associated with a range of health outcomes, including immune dysfunction. Young 
children have been identified as a particularly sensitive population, yet mechanisms of adverse 
health outcomes are understudied. Here we set out to examine the effects of iAs exposure on 
circulating serum proteins in adolescents. To identify proteins as potential indicators of disease, 
levels of total urinary arsenic (U-tAs) and its methylated metabolites were determined and serum 
proteins assessed for differences in expression. The results indicate an enrichment of TNF-
regulated immune and inflammatory response proteins that display decreased expression levels 
in relation to increasing U-tAs. Notably, when analyzed in the context of the arsenical 
proportions, there was minimal overlap between the protein lists, with the most robust response 
observed in relation to %MMAs. These data represent the first assessment of protein expression 
in serum in adolescents exposed to inorganic arsenic. 
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CHAPTER 1: INTRODUCTION 
 
 
Exposure to elevated levels of inorganic arsenic (iAs) in drinking water remains a global 
issue of concern. Over 100 million people worldwide are exposed to levels of iAs in their 
drinking water that exceed the World Health Organization’s recommended limit of 10 µg/L 
(WHO 2011). While new populations continue to be identified, those at risk of elevated exposure 
include, but are not limited to, populations in Bangladesh, Mexico, the United States, and China, 
among others (Mandal and Suzuki 2002).  
Chronic exposure to iAs is associated with a range of health outcomes in adults, 
including diabetes mellitus, impaired cognition and neurological effects, hypertension, immune 
dysfunction, and skin, lung, bladder, liver, and kidney cancers (Naujokas, Anderson et al. 2013). 
Of increasing concern, young children have been identified as a particularly sensitive population 
(Vahter 2008, Naujokas, Anderson et al. 2013). Specifically, early childhood exposure to iAs has 
been associated with outcomes manifesting during both adolescence and adulthood, including 
impaired cognitive development, increased mortality due to bladder, laryngeal, and lung cancers, 
increased non-cancer mortality due to bronchiectasis, myocardial infarction, and increased 
infection risk (Hamadani, Tofail et al. 2011, Smith, Marshall et al. 2012, Naujokas, Anderson et 
al. 2013, Rahman, Sohel et al. 2013). The long-lasting impact of iAs exposure during early 
childhood suggests that early life represents a critical period during which there is heightened 
sensitivity to the toxic effects of iAs (Vahter 2008, Naujokas, Anderson et al. 2013).    
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The mechanisms underlying the health effects of childhood exposure to iAs remain 
understudied.  Previous studies examining immune functioning in iAs-exposed children suggest 
that iAs can act as an immunosuppressant. Specifically, it has been reported that children with 
iAs exposure exhibited decreased plasma concentrations of the Th1 cytokines, TNF-α and IL-2, 
and reduced responsiveness on functional immune tests (Soto-Peña, Luna et al. 2006, Ahmed, 
Moore et al. 2014). In support of these data, there is also evidence that iAs exposure during 
childhood impairs monocyte functioning and immune-specific reactive oxygen species (ROS) 
signaling (Pineda-Zavaleta, Garcı́a-Vargas et al. 2004, Luna, Acosta-Saavedra et al. 2010). 
Paradoxically, there is also substantial evidence that iAs acts as a pro-inflammatory agent in 
children. For instance, in utero exposure to arsenic is associated with an activation of 
inflammation, including the NF-kB signaling cascade (Fry, Navasumrit et al. 2007, Bailey, Laine 
et al. 2014). Early life exposure has also been linked to iAs-induced chronic inflammation 
mediated impaired lung function (Olivas-Calderon, Recio-Vega et al. 2015). Taken together, this 
suggests that iAs can act as an immunomodulatory agent during childhood and development, 
possibly impacting maturation of the immune system during a critical period of development 
(Luna, Acosta-Saavedra et al. 2010, Dangleben, Skibola et al. 2013). Such an effect may play a 
critical role in the development of the diverse adverse health effects associated with iAs 
exposure. 
Arsenic metabolism is a multi-step process (Figure 1), with six major arsenic species that 
have been identified in human urine. These species include inorganic arsenics (iAsIII and iAsV), 
which are metabolized to the monomethylated arsenic species (MMAs), monomethylarsenous 
acid (MMAIII) and monomethylarsonic acid (MMAV). MMAs are methylated again to become 
dimethylated (DMAs), forming dimethylarsinous acid (DMAIII) and dimethylarsinic acid 
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(DMAV) (Tseng 2007). The efficiency of these methylation reactions has been identified as an 
important factor underlying the effects observed following iAs exposure as iAs, MMAs, and 
DMAs are differentially associated with As-related outcomes such as hypertension, 
atherosclerosis, cancer, and chromosomal aberrations (Huang, Tseng et al. 2007, Tseng 2007). 
 
 
Figure 1. Arsenic metabolism is a multi-step process. Arsenic is reduced from its V to III form 
by arsenic reductase, using glutathione (GSH) as an essential co-factor. Arsenic is methylated by 
Arsenic (+3 Oxidation State) Methyltransferase (AS3MT), using S-adenosyl methionine (SAM) 
as the methyl donor. 
 
Additionally, we have previously demonstrated that urinary iAs is positively associated 
with lower gestational age and newborn length, while urinary MMAs is associated with lower 
gestational age and birth weight (Laine, Bailey et al. 2015). Therefore, inter-individual 
differences in the efficiency of arsenic methylation may play a role in metabolite-specific 
associated disease risk. The impact that differences in iAs metabolism may have on protein 
expression during childhood is currently unknown.  
 Given evidence that exposure to iAs during childhood leads to abnormal immune 
functioning (Bailey, Laine et al. 2014, Olivas-Calderon, Recio-Vega et al. 2015), we hypothesized 
that childhood iAs exposure is likely to disrupt expression levels of proteins involved in immune 
function. Therefore, we conducted a proteomic assessment of serum in iAs-exposed children 
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selected from a cohort of subjects living in Comarca Lagunera, an area in North-Central Mexico. 
Moreover, in light of the knowledge that different arsenical species yield different health effects, 
we included an assessment for the relationship of proteins to %iAs, %MMAs and %DMAs. In the 
present study, we describe differences in protein expression levels in adolescents’ serum associated 
with concentrations of each class of urinary arsenic metabolites.  
 
 
5 
CHAPTER 2: METHODS 
 
Study Subjects and Sample Collection 
 The study sample for the present analysis represents a subset of 40 subjects of a cohort 
reported previously (Recio-Vega, Gonzalez-Cortes et al. 2014). Participants were children, both 
male and female, aged 6-12 years living in one of four rural communities in the Comarca 
Lagunera area, located in north-central Mexico. These communities represent those with the 
highest arsenic tap water levels (104-360 ppb) detected in the last 20 years in the area. Arsenic is 
present in the local water supply due to the over-extraction of groundwater.  Children included in 
this study had mothers who remained in these communities for the duration of their pregnancy, 
and have since remained residents of these same communities.  
 
Questionnaires 
 Information was collected through in-person interviews and included socio-demographic 
variables (education, socioeconomic status), lifetime residential history, lifestyle factors 
(secondhand smoke), parent’s occupational history, water source types (municipal tap water, 
bottled, other), current medications, medical history, and diet.  Questionnaires were completed 
by the mothers at their own residing community.  Water consumption habits, including source of 
drinking water, were ascertained through a standardized questionnaire (Recio-Vega, Gonzalez-
Cortes et al. 2014). 
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Determination of arsenic concentrations in water and in urine 
 Drinking water samples (well) were collected from each rural community included in the 
study and analyzed for inorganic arsenic levels.  Well water samples from each rural community 
are representative of the water that participants drank and is provided through the unique local 
water supply system.  Individual exposure was assessed based on U-tAs.  A first morning void 
urine sample was collected in sterile 120-mL screw-topped polypropylene containers.   Urine 
samples were analyzed as described previously (Olivas-Calderon, Recio-Vega et al. 2015). 
Briefly, samples were analyzed at the Arizona Laboratory for Emerging Contaminants, 
University of Arizona, Tuscon, Arizona. Urinary AsV, AsIII, MMAV, DMAV, and arsenobetaine 
were separated by HPLC and concentrations were analyzed by inductively coupled plasma mass 
spectrometry (ICP-MS). Standard Reference Water, SMR 1640 (NIST, Gaithersburg, MD, USA) 
and the freeze-dried Urine Reference Material for trace elements (Clinchek-control; RECIPE 
Chemicals instruments GmbH, Munich, Germany) were used as quality controls for urinary 
arsenic measurement.  
 
Assessment of protein expression in serum   
 Subjects selected for proteomic assessment are representative of the extremes of exposure 
(median U-tAs high = 399.35 µg/L, median U-tAs low = 26.03 µg/L). As detailed in our prior 
publication (Bailey, Laine et al. 2014), the relative expression levels of 507 proteins were 
determined using the Biotin Label-based Human Antibody Array I, L series 507 (RayBiotech, 
Norcross,GA), which includes cellular signaling proteins such as cytokines, chemokines, growth 
factors, angiogenic factors, soluble receptors, and soluble adhesion molecules. Protein labeling 
and hybridization were carried out according to the manufacturer’s instructions using 40 µl of 
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each serum sample. Briefly, primary amines of serum proteins are biotinylated and hybridized to 
a membrane array containing antibodies specific for each of the 507 protein targets, incubated 
with a horseradish peroxidase (HRP)-streptavidin conjugate, and detected by chemiluminescence 
following incubation with an HRP substrate buffer. The protein array contains two types of 
positive controls: a biotin-labeled protein, independent of the sample, that is spotted on each 
array in a series of known concentrations enabling signal intensity normalization across arrays, 
as well as an internal positive control which is an exogenous, nonmammalian protein added to 
the serum sample prior to biotinylation, serving as a control for the labeling and incubation steps. 
 
Statistical Analyses 
 Statistical analyses were performed using Partek Genomics Suite software (version 6.6; 
Partek, Inc., St Louis, MO). All data were analyzed for their distribution patterns and 
homogeneity, and filtering was used to remove any non-expressed proteins. Multivariable 
regression models were used to examine relationships between individual arsenic measures (U-
tAs, %iAs, %MMAs, %DMAs) and the normalized, background-subtracted signal intensities of 
the 393 proteins. Age, sex, and body mass index (BMI) were selected as a priori covariates due 
to their potential influence on protein expression levels and were controlled for in the models. 
Statistical significance was defined as p < 0.05, with false discovery (type II error) controlled for 
using a q-value <0.1.  
 
Functional Analyses of Proteins 
 Proteins that showed statistically significant association with either U-tAs, %iAs, 
%MMA, or %DMA were analyzed for biological functions, canonical pathways, upstream 
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regulatory molecules, and interacting molecular networks using Ingenuity Pathway Analysis 
software (Ingenuity Systems,  Redwood City, CA). Proteins were also analyzed for KEGG 
pathway molecular interactions using The Database for Annotation, Visualization and Integrated 
Discovery (DAVID; https://david.ncifcrf.gov/), and immunologic signatures using Gene Set 
Enrichment Analysis (GSEA, http://software.broadinstitute.org/gsea/index.jsp).  
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CHAPTER 3: RESULTS 
 
Study characteristics 
 Demographic characteristics of the study sample (n=40), as well as those of the entire 
cohort (n=358), can be found in Table 1.  These subjects were selected as representatives of the 
extremes of exposure (median U-tAs high = 399.35 µg/L, median U-tAs low = 26.03 µg/L). 
Anthropometric characteristics recorded include sex, age, (years) weight (kg), and BMI (calculated 
as weight/height2).  The majority of the subjects were male (n=22, 55%), have lived at their current 
residence their entire lives (n=36, 90%), and were, on average 9.3 years of age (range 7-12). Other 
possible sources of arsenic exposure, including diet (seafood, rice and others), agrochemicals, 
fuels, preservatives or other compounds containing arsenicals, were negligible (Recio-Vega, 
Gonzalez-Cortes et al. 2014).   
 
 Indicators of arsenic exposure examined include total urinary arsenic (U-tAs; µg/L), as 
well as the percentages of inorganic arsenic (iAs), monomethylated arsenicals (MMAs) and 
dimethylated arsenicals (DMAs) as indicators of arsenic metabolism. All samples were within 
detectable limits and U-tAs, defined as the sum of U-iAs, U-MMAs and U-DMAs, ranged from 
5.33 g/L to 664.53 g/L. The average proportions of U-tAs were 24.4% iAs, 14.9% MMAs, 
and 60.7% DMAs. Arsenic tap water levels and urinary arsenic levels were highly correlated (R2 
= 0.69). 
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Table 1. Demographic and exposure characteristics of study population 
 
 Study Sample Cohort 
 Mean, Median (Range) 
or n (n%) 
Mean, Median (Range) 
or n (n%) 
Sex   
       male 22 (55%) 188 (53%) 
       female 18 (45%) 170 (47%) 
age (years) 9.3, 9.5 (7-12) 8.9, 9.0 (6-12) 
height (m) 1.4, 1.38 (1.18-1.63) 1.3, 1.3 (1.1-1.7) 
weight (kg) 37.0, 34.5 (17.0-82.0) 34.1, 31.43 (15.9-82.0) 
BMI* 18.3, 17.8 (7.3-32.9) 17.9, 16.7 (7.2-33.8) 
time current address (yrs) 9.3, 9.0 (5-12) 8.4, 8.0 (5-12) 
U-As Total (µg/L ) 220.0, 135.11 (5.33-664.53) 141.15, 114.59 (4.72-894.3) 
       Low exposure 32.94, 26.03 (5.33-109.13) n/a 
       High exposure 384.73, 399.35 (159.82-610.51) n/a 
%iAs 21.6, 13.8 (5.44-84.4) 21.4, 20.58 (3.26-91.38) 
%MMA 14.5, 12.7 (7.14-68.42) 13.23, 4.0 (2.06-42.80) 
%DMA 58.8, 68.9 (1.6-81.9) 61.91, 21.64 (0.99-89.83) 
* calculated as weight/height2 
 
 
Identification of proteins associated with total urinary arsenic and arsenic metabolites 
Multivariable analyses identified 58 proteins that displayed a statistically significant 
association (p<0.05, q=0.1) with U-tAs, the vast majority of which are negatively associated 
(n=56, 96.6%) (Appendix 1). When analyzed in the context of the arsenical proportions, 8 
proteins were significantly (p<0.05) associated with %iAs, 18 proteins were associated with 
%MMAs, and 11 proteins displayed significant association with %DMAs.  There were no 
proteins identified in common across all three methylated metabolites (Figure 2, Appendix 1).  
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Figure 2. Total number of %iAs, %MMA, and %DMA associated proteins as well as 
commonality among arsenical associated lists. Venn diagram illustrating the number of serum 
protein that have a statistically significant association between expression levels and urinary 
proportions of iAs, MMAs and/or DMAs. 
 
 
The 58 proteins identified as being significantly associated with U-tAs were analyzed for 
functional interactions (Appendix 2). Canonical pathway analysis revealed a strong enrichment 
of cytokine-mediated communication between immune cells (p= 1.12 x 10-2), comprised largely 
of a family of interleukins, including Interferon, Alpha 13 (IFNA1/IFNA13) and Chemokine (C-
X-C Motif) Ligand 8 (CXCL8). Network analysis revealed a protein cluster involved in cellular 
development, cellular growth and proliferation (p= 1 x 10-34), which interacts with the major 
histocompatibility complex (MHC), class II (Figure 3). 
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Figure 3. Interacting network of U-tAs associated serum proteins and upstream regulation by 
TNF. Interacting network of U-tAs-associated serum proteins are identified (A). TNF is 
predicted to regulate the expression of the majority (n=36, 62%) of the U-tAs associated proteins 
(B). Proteins are displayed as predicted to be upregulated (red) or downregulated (green). 
 
 
 A similar approach was used to investigate the pathways that were enriched among the 
proteins associated with the arsenical proportions. In relation to %iAs, canonical pathway 
analysis revealed several proteins involved in immune surveillance (p= 2.90 x 10-4), and include 
Platelet-Derived Growth Factor C (PDGFC) and Platelet-Derived Growth Factor D (PDGFD). 
Network analysis revealed a cellular growth and proliferation component (p=1.00 x 10-24), 
mediated by ERK 1/2 kinase and containing several members of the PDGF family, which are 
responsible for cellular proliferation and differentiation.  
In relation to %MMAs, altered proteins were associated with an apoptosis signaling 
pathway (p=1.09 x 10-9), including Tumor Necrosis Factor (Ligand) Superfamily, Member 10 
(TNFSF10) and many related TNF receptor superfamily (TNFRSF) members and vascular 
endothelial growth factors B and C (VEGFB, VEGFC). Network analysis centered on 
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organismal and cardiovascular system development and connective tissue disorders (p= 1 x 10-
47), modulated by ERK 1/2 and NFkB.  
In relation to %DMAs, proteins involved in immune surveillance, specifically 
macropinocytosis signaling (p= 3.36x10-8), were altered and include Platelet Derived Growth 
Factor B (PDGFB), PDGFC, and PDGFD. Network analysis reveals cellular growth and 
proliferation (p= 1 x 10-33), and includes many members of the PDGF family modulated by 
NFkB.  Additionally, DAVID was used to confirm all pathway analyses and showed Cytokine-
cytokine receptor interaction as the common top KEGG pathway for U-tAs (p= 3.76 x 10-21),    
%iAs (p=0.015), %MMAs (p= 6.80 x 10-09), and %DMAs (p=0.015). 
  
Transcription factor regulation of arsenic-associated proteins  
 Analysis was performed for all arsenic-associated protein lists in order to identify key 
upstream regulators, including cell signaling molecules and transcription factors (Appendix 2). 
Tumor necrosis factor (TNF) was found to be the top regulator of the U-tAs-associated proteins 
(p=1.59 x 10-27), and was predicted to be inhibited in relation to U-tAs. For the individual 
arsenicals, Dual Specificity Phosphatase 5 (DUSP5) was the top regulator of the %iAs-
associated proteins (p= 1.98 x 10-5), pyruvic acid was the top regulator of the %MMAs-
associated proteins (p= 1.98 x 10-10), and for %DMAs-associated proteins, Fibroblast Growth 
Factor 2 (Basic) (FGF2) (p= 1.47 x 10-5) was the most significant regulator. Because of the small 
number of proteins in each arsenical-associated list, predicted effects (i.e., activation or 
inhibition) could not be established. 
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CHAPTER 4: DISCUSSION 
 
Early childhood exposure to iAs has been associated with adverse health outcomes 
manifesting during both adolescence and adulthood (Hamadani, Tofail et al. 2011, Smith, 
Marshall et al. 2012, Naujokas, Anderson et al. 2013, Rahman, Sohel et al. 2013). Moreover, 
inter-individual differences in the efficiency of arsenic metabolism has been shown to influence 
iAs-associated disease, with high urinary proportions of MMAs associated with detrimental 
outcomes such as cancer of the urinary bladder, skin cancer, and cardiovascular disease (Huang, 
Tseng et al. 2007, Tseng 2007). Despite this, the effects of childhood exposure to iAs remain 
understudied, particularly in terms of effects on cellular and molecular functions.  In the present 
study, we set out to identify biological pathways which may be modulated at the protein level by 
early life arsenic exposure. Using a subset of 40 subjects from a previously reported cohort 
(Recio-Vega, Gonzalez-Cortes et al. 2014), we have identified proteins with expression levels 
associated with inorganic arsenic exposure. While we have previously examined prenatal  
arsenic-associated differences in the expression in the newborn cord serum proteome (Bailey, 
Laine et al. 2014), to our knowledge this is the first study to examine differences in the 
expression of proteins in children’s serum associated with total urinary arsenic, as well as 
proportions of each class of urinary arsenic metabolites. The proteins that showed altered 
expression largely fell into functional categories of inflammation and immune response. 
Additionally, TNF was identified as a predicted upstream regulator of the U-tAs proteome, as 
well as a mediator of metabolite-dependent differences in identified proteins and regulators.  
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We demonstrate a massive repression of immune-associated cytokines as U-tAs levels 
increase. Interestingly, TNF was identified as a key regulator of these repressed proteins. TNF 
has a known roll in immune response, apoptosis, inflammation, and cell migration, as well as 
having been implicated in numerous diseases (Naujokas, Anderson et al. 2013). Our prior 
research highlight TNF as a regulator of the newborn proteome (Bailey) as well as the newborn 
transcriptome (Fry, Navasumrit et al. 2007).  Here we show that many of the identified 
suppressed proteins are involved in the major histocompatibility (MCH) complex II, which is 
responsible for triggering localized inflammation and B cell activation in the adaptive immune 
response (Andrew, Jewell et al. 2008), and included many interleukins and interferons. These 
data highlight altered expression of cytokines known to play a role in adaptive and innate 
immune signaling and could provide a mechanistic hypothesis for increased risk of infection 
(Farzan, Li et al. 2016).   
When analyzed in relation to inter-individual differences in arsenic metabolism in 
adolescents, we found minimal overlap between the %iAs, %MMAs and %DMAs-associated 
proteins. These data suggest a urinary arsenic metabolite-specific response to iAs exposure and 
reflects the strong inter-individual component to the response. The most robust response in terms 
of differential protein expression was observed in relation to %MMAs. This finding is interesting 
as inter-individual differences in iAs metabolism, particularly elevation in %MMAs, have been 
shown to be associated with disease risk (Huang, Tseng et al. 2007, Tseng 2007, Laine, Bailey et 
al. 2015). In our prior work, we have shown inter-individual differences in iAs metabolism as it 
relates to epigenetic signatures of disease (Bailey, Laine et al. 2014, Rager, Bailey et al. 2014). 
Proteins associated with %MMAs include many TNF superfamily (TNFSF) members. Among 
these are TNFSF10 and TNFSF15 previously  shown to play roles in hepatic and cardiovascular 
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disease (Guha Mazumder 2005, Straub, Stolz et al. 2007, Coulon, Heindryckx et al. 2011, Ghatak, 
Biswas et al. 2011, Naujokas, Anderson et al. 2013, Mohammed Abdul, Jayasinghe et al. 2015). 
In addition to the TNFSF, members of the VEGF family also displayed a positive association with 
%MMAs. The VEGF family is a known regulator of angiogenesis (Detoraki, Staiano et al. 2009). 
VEGFB has been shown to play a role in cancer metastasis and tumor invasion (Yang, Zhang et 
al. 2015) and VEGFB expression has been found to be upregulated in ovarian, colorectal, renal, 
and prostate cancer (Gunningham, Currie et al. 2001, Hanrahan, Currie et al. 2003). VEGFC also 
plays a role in metastatic spread of certain tumor types (Gunningham, Currie et al. 2001). These 
data highlight differences in the expression of proteins with known association to arsenic-
associated diseases.  
While we have identified a large TNF-mediated response in relation to U-tAs with 
metabolite-specific differences, the study is not without its limitations. Despite being one of the 
largest proteomic studies to date, we have only assessed a fraction of the thousands of circulating 
serum proteins and due to the small sample size in the present study, associations seen should be 
confirmed in a larger cohort. Additionally, it possible that other environmental exposures and/or 
potential confounding variables not assessed in the present study may contribute to the observed 
differences.  Moreover, while proteins identified have known associations with arsenic-related 
adverse outcomes it is unknown if the current cohort will present with such diseases. Future 
studies could examine both genomic and epigenetic mechanisms that may underlie the observed 
functional differences in protein expression (Bailey, Smith et al. 2016).  
 In summary, the data from the present study suggest that iAs acts as an 
immunomodulator, and also that it does so in a metabolite-specific manner. The proteomic 
differences in expression seen here highlight the role of iAs in possibly impacting maturation of 
  17  
the immune system during a critical period of development (Luna, Acosta-Saavedra et al. 2010), 
and as such, has the potential to alter disease risk later in life. Early childhood exposure to iAs 
has been associated with outcomes manifesting during both adolescence and adulthood, and the 
long-lasting impact of iAs exposure during early childhood suggests that early life represents a 
critical period during which there is heightened sensitivity to the toxic effects of iAs (Vahter 
2008, Naujokas, Anderson et al. 2013). These data inform potential mechanisms by which early 
life and childhood exposure to iAs may be linked to detrimental health outcomes. 
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APPENDIX  1: SUPPLEMENTARY TABLE 1 
 
Supplementary Table 1.  Identification of proteins associated with total urinary arsenic (U-tAs) and proportions of arsenic metabolites         
(%iAs, %MMAs, %DMAs). Bold denotes statistical significance.  
 
Protein 
Symbol Protein Name Genbank ID 
U-tAs      
p-val 
U-tAs      
q-val 
U-tAs       
Beta 
%iAs       
p-val 
%iAs       
Beta 
%MMA     
p-val 
%MMA    
Beta 
%DMA    
p-val 
%DMA    
Beta 
ACVR1  
Activin A 
receptor type 1 NM_001105.4 0.0097 0.0883 0.4032 0.9293 -0.0146 0.7729 -0.0473 0.8996 0.0207 
CCL18 
Chemokine (C-C 
Motif) Ligand 18  NM_002988 0.0131 0.0902 -0.4097 0.9918 0.0018 0.5778 0.0961 0.9300 -0.0152 
CXCL12 
Chemokine (C-
X-C Motif) 
Ligand 12 NM_000609 0.0198 0.0909 -0.3834 0.6177 0.0855 0.0986 0.2775 0.4769 -0.1215 
EDA2R  
X-linked 
ectodysplasin-A2 
receptor NM_021783 0.7142 0.4957 0.0639 0.3523 0.1614 0.0133 0.4127 0.2153 -0.2139 
FLT4 
Fms-Related 
Tyrosine Kinase 
4 NP_002011.2 0.9024 0.5469 -0.0214 0.5218 -0.1115 0.0296 0.3665 0.7461 0.0565 
GPC3 Glypican 3 NM_00484 0.0218 0.0918 -0.3752 0.6067 0.0875 0.5085 -0.1122 0.6854 -0.0689 
GPNMB 
Glycoprotein 
(Transmembrane) 
Nmb NM_001005340.1 0.0196 0.0909 -0.3854 0.6265 -0.0836 0.9730 -0.0058 0.6345 0.0817 
HBEGF 
Heparin-binding 
Epidermal 
Growth factor NM_001945 0.0241 0.0947 -0.3635 0.4124 0.1366 0.8680 -0.0278 0.4419 -0.1282 
HGFR 
Hepatocyte 
growth factor 
receptor NP_000236.2  0.2710 0.2882 -0.1855 0.0503 0.3233 0.4886 0.1173 0.0460 -0.3291 
  
1
9 
IFNAR1 
Interferon alpha / 
beta receptor 1 NM_000629.2 0.0168 0.0909 -0.3982 0.9882 -0.0026 0.4492 -0.1311 0.9046 0.0209 
IFNAR2 
Interferon alpha / 
beta receptor 2 NM_000874 0.0068 0.0850 -0.4474 0.7065 0.0658 0.3869 -0.1504 0.8077 -0.0425 
IFNB1 Interferon beta 1 NP_002167.1 0.0087 0.0883 -0.4324 0.9817 -0.0040 0.1934 -0.2229 0.8398 0.0351 
IFNG Interferon gamma NM_000619 0.0064 0.0850 -0.4452 0.9154 0.0183 0.1571 -0.2405 0.9263 0.0160 
IFNGR1 
Interferon gamma 
receptor 1 NM_000416 0.0040 0.0645 -0.4653 0.7794 0.0481 0.2235 -0.2070 0.9187 -0.0175 
IGFBP1 
Insulin-like 
growth factor 
binding proteins 
1 NM_001013029 0.0020 0.0645 -0.4916 0.6951 0.0670 0.3847 -0.1479 0.7967 -0.0441 
IGFBP2 
Insulin-like 
growth factor 
binding proteins 
2 NM_000597 0.0199 0.0909 -0.3659 0.6689 0.0699 0.6864 -0.0660 0.7212 -0.0584 
IGFBP3 
Insulin-like 
growth factor 
binding proteins 
3 NM_001013398 0.0018 0.0645 -0.4895 0.5559 0.0990 0.8346 -0.0352 0.5892 -0.0908 
IGFBP7 
Insulin-Like 
Growth Factor 
Binding Protein 7 NM_001253835.1 0.0028 0.0645 -0.4450 0.5445 0.0963 0.6734 0.0671 0.5186 -0.1026 
IGFI 
Insulin-Like 
Growth Factor 1 
(Somatomedin C) NM_000618 0.0036 0.0645 -0.4616 0.3632 0.1527 0.8279 0.0367 0.3628 -0.1529 
IL11 Interleukin 11 NM_000641 0.2372 0.2655 -0.2002 0.0429 0.3359 0.4338 0.1334 0.0381 -0.3436 
IL13RA2 
Interleukin 13 
receptor alpha 2 NM_000640 0.0246 0.0947 -0.3772 0.7466 -0.0563 0.3317 -0.1681 0.6542 0.0780 
IL15 Interleukin 15 NM_000585 0.0171 0.0909 -0.3984 0.7216 -0.0621 0.2347 -0.2051 0.6100 0.0888 
IL15RA 
Interleukin 15 
receptor alpha NM_172200 0.0193 0.0909 -0.3904 0.7686 -0.0511 0.2185 -0.2115 0.6487 0.0791 
IL16 Interleukin 16 NM_172217 0.0111 0.0883 -0.4190 0.9827 -0.0038 0.2627 -0.1923 0.8599 0.0306 
IL17A Interleukin 17 NM_002190 0.0090 0.0883 -0.4261 0.8779 -0.0264 0.2832 -0.1828 0.7659 0.0511 
  
2
0 
IL17B Interleukin 17B NM_014443 0.0095 0.0883 -0.4179 0.8588 -0.0302 0.3705 -0.1510 0.7665 0.0504 
IL17C Interleukin 17C NM_013278 0.0142 0.0902 -0.3816 0.9853 0.0030 0.6759 -0.0680 0.9675 0.0066 
IL17D Interleukin 17D NM_138284 0.0032 0.0645 -0.4502 0.8869 0.0232 0.6395 -0.0762 0.9426 -0.0117 
IL17F Interleukin 17F NM_052872 0.0028 0.0645 -0.4634 0.7662 0.0493 0.6039 -0.0858 0.8298 -0.0356 
IL17RB 
Interleukin 17B 
receptor NM_172234 0.0033 0.0645 -0.4609 0.9577 0.0089 0.5335 -0.1040 0.9715 0.0060 
IL17RC 
Interleukin 17 
receptor C NM_032732 0.0157 0.0909 -0.3864 0.5031 0.1116 0.6901 -0.0666 0.5544 -0.0986 
IL1A 
Interleukin-1 
alpha NM_000575 0.0209 0.0909 -0.3806 0.2374 0.2006 0.8954 0.0226 0.2456 -0.1972 
IL2 Interleukin 2 NM_000586 0.0105 0.0883 -0.4252 0.9783 -0.0047 0.3439 -0.1642 0.8745 0.0276 
IL25 Interleukin 17E NM_172314 0.0022 0.0645 -0.4785 0.6599 0.0736 0.7495 -0.0535 0.7034 -0.0637 
IL27 
Interleukin-27 
subunit alpha NM_145659 0.0212 0.0909 -0.3812 0.9133 -0.0187 0.3031 -0.1759 0.8038 0.0428 
IL28A Interleukin-28A NM_172138 0.0145 0.0902 -0.3959 0.6518 -0.0764 0.3054 -0.1723 0.5621 0.0980 
IL29 Interleukin-29 NM_172140 0.0133 0.0902 -0.4072 0.5031 -0.1150 0.7844 -0.0471 0.4926 0.1179 
IL2RA 
Interleukin 2 Rec
eptor, Alpha NM_000417.2 0.0075 0.0850 -0.4442 0.7537 -0.0550 0.2263 -0.2097 0.6371 0.0826 
IL2RB 
Interleukin 2 
Receptor, Beta NM_000878 0.0073 0.0850 -0.4419 0.8717 0.0281 0.2472 -0.1993 0.9966 0.0007 
IL2RG 
Interleukin 2 
Receptor, 
Gamma NM_000206 0.0062 0.0850 -0.4475 0.8349 0.0361 0.3396 -0.1642 0.9453 -0.0119 
IL31 Interleukin-31 NM_001014336 0.0102 0.0883 -0.4048 0.7376 0.0555 0.5097 -0.1089 0.8167 -0.0384 
IL31RA 
Interleukin-31 
Receptor A NM_139017 0.0138 0.0902 -0.3886 0.6953 0.0647 0.5173 -0.1067 0.7733 -0.0476 
IL3RA 
Interleukin-3 
receptor subunit 
alpha NM_002183 0.0014 0.0645 -0.5067 0.6848 0.0696 0.4518 -0.1286 0.7739 -0.0493 
IL4 Interleukin 4 NM_172348 0.0009 0.0645 -0.5211 0.6534 0.0764 0.6015 -0.0889 0.7181 -0.0615 
IL4R 
Interleukin-4 
receptor alpha 
chain NM_001008699 0.0021 0.0645 -0.4955 0.8377 -0.0354 0.8899 -0.0239 0.8278 0.0376 
  
2
1 
IL7R 
Interleukin-7 
receptor subunit 
alpha NP_002176.2 0.0040 0.0645 -0.4547 0.4267 0.1329 0.9951 -0.0010 0.4427 -0.1284 
IL8 Interleukin 8 NM_000584 0.0183 0.0909 -0.3819 0.4580 0.1248 0.9545 -0.0096 0.4780 -0.1194 
INHBA  Inhibin, Beta A NM_002192.2 0.0263 0.0998 0.3398 0.3749 0.1401 0.8732 0.0253 0.3785 -0.1390 
INHBB Inhibin, Beta B NP_002184.2 0.0066 0.0850 -0.4295 0.7378 0.0559 0.7646 -0.0500 0.7782 -0.0470 
KIT 
V-Kit Hardy-
Zuckerman 4 
Feline Sarcoma 
Viral Oncogene 
Homolog NP_000213.1 0.0196 0.0909 -0.3818 0.7820 0.0472 0.2073 0.2124 0.6580 -0.0754 
LCN1 Lipocalin-1 NM_002297 0.0228 0.0927 -0.3763 0.3310 -0.1660 0.2535 -0.1944 0.2704 0.1878 
LRP1 
Prolow-density 
lipoprotein 
receptor-related 
protein 1 NM_002332 0.0147 0.0902 -0.3986 0.7725 -0.0494 0.2185 -0.2079 0.6523 0.0769 
LTB  
Lymphotoxin 
beta (TNFR 
Superfamily, 
Member 3) NM_009588 0.0186 0.0909 -0.3706 0.8988 -0.0209 0.5577 -0.0960 0.8375 0.0337 
LTBR 
Lymphotoxin 
beta receptor 
(TNFR 
Superfamily, 
Member 3) NM_002342 0.0143 0.0902 -0.3906 0.9040 0.0201 0.7164 -0.0605 0.9476 -0.0110 
MMP11 
Matrix 
Metallopeptidase 
11 NM_005940 0.0226 0.0927 -0.3717 0.5729 -0.0954 0.3424 -0.1599 0.4974 0.1147 
MMP14 
Matrix 
Metallopeptidase 
14 (Membrane-
Inserted) NM_004995 0.0122 0.0902 -0.4027 0.9006 -0.0211 0.6989 -0.0651 0.8610 0.0295 
MMP-15 
Matrix 
metalloproteinase
-15 NM_002428 0.0173 0.0909 -0.3828 0.9275 0.0153 0.9077 -0.0195 0.9428 -0.0120 
  
2
2 
NRCAM 
Neuronal cell 
adhesion 
molecule NP_001032209.1 0.0243 0.0947 -0.3800 0.1244 -0.2645 0.8318 -0.0372 0.1296 0.2611 
NRG3 
Pro-neuregulin-3, 
membrane-bound 
isoform XM_166086 0.5694 0.4402 -0.0991 0.0482 -0.3347 0.2681 -0.1915 0.0380 0.3506 
OSTN Osteocrin NM_198184 0.0095 0.0883 -0.4194 0.9473 -0.0112 0.7407 0.0562 0.9860 0.0030 
PDGFB 
Platelet-derived 
growth factor 
subunit B NP_002599.1 0.1536 0.2066 -0.2443 0.0651 0.3126 0.2294 0.2067 0.0498 -0.3313 
PDGFC 
Platelet-derived 
growth factor C NM_016205 0.1593 0.2092 -0.2418 0.0268 0.3719 0.1752 0.2331 0.0190 -0.3924 
PDGFD 
Platelet-derived 
growth factor D NM_025208 0.3386 0.3247 -0.1652 0.0174 0.3963 0.1510 0.2458 0.0117 -0.4177 
PPBP 
Pro-Platelet Basic 
Protein 
(Chemokine (C-
X-C Motif) 
Ligand 7) NM_002704 0.2816 0.2935 -0.1845 0.0329 0.3563 0.2831 0.1839 0.0261 -0.3704 
SCF Stem Cell Factor NP_000890.1 0.0212 0.0909 -0.3769 0.8750 0.0268 0.2152 0.2086 0.7459 -0.0551 
Siglec-9 
Sialic acid-
binding Ig-like 
lectin 9 NP_055256.1 0.1715 0.2164 -0.2357 0.0669 0.3124 0.1077 0.2758 0.0445 -0.3408 
SLC2A3 
Glucose 
transporter 3 NM_006931 0.0605 0.1285 -0.3073 0.8080 -0.0408 0.0498 -0.3204 0.6151 0.0844 
SLPI 
Secretory 
Leukocyte 
Peptidase 
Inhibitor NM_003064 0.2497 0.2769 -0.1981 0.0177 0.3953 0.1585 0.2415 0.0121 -0.4161 
TFPI 
Tissue factor 
pathway inhibitor NM_006287 0.7176 0.4957 0.0612 0.0302 -0.3543 0.6011 -0.0884 0.0298 0.3550 
TGFBR2 
TGF-beta 
receptor type-2 NM_001024847.2 0.2367 0.2655 -0.2029 0.7096 0.0645 0.0322 0.3585 0.5145 -0.1126 
  
2
3 
TGFBR3 
TGF-beta 
receptor type III NM_003243 0.3210 0.3173 -0.1724 0.5610 0.1015 0.0194 0.3926 0.3786 -0.1532 
TGFR2 
TGF-
Beta Receptor 
Type IIB NM_001024847 0.2066 0.2446 -0.2171 0.5181 0.1121 0.0202 0.3878 0.3463 -0.1628 
THPO Thrombopoietin NM_000460 0.3252 0.3185 -0.1713 0.5330 0.1090 0.0253 0.3776 0.3635 -0.1584 
TMPO Thymopoietin NP_003267.1 0.3603 0.3282 -0.1581 0.0404 0.3452 0.0859 0.2921 0.0251 -0.3748 
TNFRSF 
10A  
Tumor necrosis 
factor receptor 
superfamily 
member 10A NP_003835.2 0.7093 0.4957 -0.0649 0.7890 0.0466 0.0231 0.3809 0.5712 -0.0985 
TNFRSF 
10B 
Tumor necrosis 
factor receptor 
superfamily 
member 10B NP_003833.4 0.9646 0.5665 -0.0078 0.8296 0.0376 0.0375 0.3518 0.6234 -0.0857 
TNFRSF 
10C 
Tumor Necrosis 
Factor Receptor 
Superfamily, 
Member 10C NM_003841 0.7995 0.5176 -0.0445 0.4532 0.1309 0.0178 0.3980 0.2940 -0.1824 
TNFRSF 
10D 
Tumor Necrosis 
Factor Receptor 
Superfamily, 
Member 10D NM_003840 0.8624 0.5335 -0.0304 0.4184 0.1410 0.0099 0.4295 0.2570 -0.1966 
TNFRSF 
11B 
Tumor Necrosis 
Factor Receptor 
Superfamily, 
Member 11b NP_002537.3 0.0165 0.0909 -0.3860 0.9787 -0.0045 0.6172 0.0839 0.9648 -0.0074 
TNFSF10 
Tumor Necrosis 
Factor (Ligand) 
Superfamily, 
Member 10 NP_003801.1 0.8216 0.5245 -0.0393 0.8321 0.0369 0.0280 0.3689 0.6151 -0.0874 
TNFSF11 
Tumor Necrosis 
Factor (Ligand) 
Superfamily, 
Member 11 NM_033012 0.9780 0.5703 -0.0048 0.3451 0.1637 0.0271 0.3717 0.2228 -0.2104 
  
2
4 
TNFSF15 
Tumor necrosis 
factor ligand 
superfamily 
member 15 NM_005118 0.8792 0.5371 -0.0265 0.5502 0.1037 0.0143 0.4076 0.3628 -0.1574 
TNFSF4 
Tumor Necrosis 
Factor (Ligand) 
Superfamily, 
Member 4 NM_003326 0.0113 0.0883 -0.4071 0.8525 0.0314 0.4328 0.1317 0.7723 -0.0488 
VEGFB  
Vascular 
endothelial 
growth factor B NM_003377 0.7961 0.5169 -0.0450 0.9062 0.0205 0.0206 0.3873 0.6700 -0.0741 
VEGFC 
Vascular 
endothelial 
growth factor C NM_005429 0.8025 0.5181 -0.0435 0.8381 0.0355 0.0146 0.4061 0.5991 -0.0913 
VEGFD 
Vascular 
endothelial 
growth factor D NM_182925.4 0.9529 0.5644 -0.0103 0.7751 0.0498 0.0182 0.3946 0.5518 -0.1034 
WISP1 
WNT1-inducible-
signaling 
pathway protein 1 NP_003873.1 0.9567 0.5644 0.0095 0.2142 0.2140 0.0170 0.3985 0.1248 -0.2628 
   
  
2
5 
APPENDIX  2: SUPPLEMENTARY TABLE 2 
Supplementary Table 2. Canonical IPA pathways (A.), canonical KEGG pathways (B.), Upstream regulators (C.), and IPA 
molecular networks (D.) of the As-and arsenical-associated proteins. 
 
A. IPA pathways    
 Pathway   Canonical pathway description  p-value Associated proteins in pathway  
 
U-tAs 
Role of Cytokines in Mediating Communication 
between Immune Cells 
1.12E-02 
CXCL8, IFNA1/IFNA13, IFNB1, 
IFNG, IFNL1, IL2, IL4, IL15, IL25, 
IL27, IL17A, IL17F, IL1A 
 %iAs Macropinocytosis Signaling 2.90E-04 PDGFD, PDGFC 
 
%MMA Retinoic acid Mediated Apoptosis Signaling 
1.09E-09 
TNFRSF10A, TNFRSF10B, 
TNFRSF10C, TNFRSF10D, TNFSF10 
 %DMA Macropinocytosis Signaling 3.36E-08 MET, PDGFB, PDGFC, PDGFD 
      
B. KEGG pathways    
 Pathway   Canonical pathway description  p-value Associated proteins in pathway  
 
U-tAs Cytokine-cytokine receptor interaction 3.76E-21 
CXCL12, CXCL8, ACVR1, IFNGR1, 
IFNG, IL1A, IL15RA, IL15, IL17RB, 
IL17A, IL2RB, IL2RG, IL2, IL25, 
IL3RA, IL4R, IL4, LTBR, LTB, 
TNFSF4 
 %iAs Cytokine-cytokine receptor interaction 1.50E-02 IL11, PDGFC, CXCL7 
 
%MMA Cytokine-cytokine receptor interaction 6.80E-09 
FIGF, EDA2R, TGFBR2, TNFSF11, 
TNFSRF10C, TNFSRF1D, VEGFB, 
VEGFC  
 %DMA Cytokine-cytokine receptor interaction 1.50E-02 IL11, PDGFC, CXCL7 
 
 
 
 
   
  
2
6 
C. Upstream 
regulators 
 Pathway   Canonical pathway description  p-value Predicted Activation 
 U-tAs TNF 1.59E-27 Inhibited 
 %iAs DUSP5 1.98E-05 no prediction 
 %MMA Pyruvic acid 1.98E-10 no prediction 
 %DMA FGF2 1.47E-05 no prediction 
      
D. IPA networks    
 
Network 
Most significant associated 
functions 
p-value 
Number of 
associated 
proteins in 
network 
Molecules in network 
 
U-tAs 
Cellular Development, 
Cellular Growth and 
Proliferation, Hematological 
System Development and 
Function 
1.00E-34 16 
Eotaxin, ERK1/2, Fibrin, HDL, Ifn, IFN 
alpha/beta, IFNA1/IFNA13, IFNL1, 
IFNL2, Iga, IL23, IL25, IL27, IL31, 
Il-4 receptor, Il15r, IL15RA, IL17B, 
IL17C, IL17D, IL17F, IL17RB, 
IL17RC, IL2RG, IL31RA, 
INTERLEUKIN, LTBR, MHC Class II 
(complex), MHC II, Notch, Oas, Pro-
inflammatory Cytokine, SAA, TH1 Cytokine, 
Tlr 
 
%iAs 
Cardiovascular Disease, 
Hematological Disease, 
Cellular Growth and 
Proliferation 
1.00E-24 8 
Akt, BCL2, CELA2A, CLEC11A, CTSG, 
DUSP5, ERK1/2, F2, F10, F3-F7, GP5, 
HABP2, HPSE, IL11, Il8r, LOX, MMP15, 
NFkB (complex), NRG3, PDGF (family), 
PDGF-CC, PDGF-DD, PDGFC, PDGFD, 
PMAIP1, PPBP, PROK1, PROS1, PRSS3, 
S100a7a, SLPI, TFPI, TMPO, Vegf, 
VEGFA 
  
2
7 
 
%MMA 
Organismal Development, 
Cardiovascular System 
Development and Function, 
Connective Tissue Disorders 
1.00E-47 16 
caspase, Collagen(s), death receptor, DR4/5, 
ERK1/2, FIGF, FLT4, Focal adhesion 
kinase, FSH, growth factor receptor, Growth 
hormone, IL1, Immunoglobulin, Mapk, p70 
S6k, Pro-inflammatory Cytokine, SLC2A3, 
Tgf beta, TGFBR, TGFBR2, TGFBR3, 
THPO, Tnf (family), TNFRSF10A, 
TNFRSF10B, TNFRSF10C, 
TNFRSF10D, TNFSF10, TNFSF11, 
TNFSF15, Trail-R, Vegf, VEGFB, 
VEGFC, WISP1 
 
%DMA 
Cellular Growth and 
Proliferation, Organismal 
Development, Cancer 
1.00E-33 11 
Akt, Ap1, Collagen(s), ERK, ERK1/2, GP130 
dimer, Histone h3, IL11, Jnk, Mapk, MET, 
Met dimer, NFkB (complex), NRG3, P38 
MAPK, p85 (pik3r), Pdgf (complex), PDGF 
(family), PDGF-CC, PDGF-DD, PDGFB, 
PDGFC, PDGFD, PI3K (complex), 
PPBP, Pro-inflammatory Cytokine, PROK1, 
Ras, S100A12, SIGLEC9, SLPI, TFPI, 
Tgf beta, TMPO, Vegf 
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